In a comprehensive global review published in Lancet Microbe, the World Health Organization has identified SynAct Pharma’s resomelagon as one of only six dengue therapeutic candidates with sufficient evidence to support further clinical development. Resomelagon is the only host-directed therapy in the group. BioStock contacted Thomas Jonassen, Chief Scientific Officer of Synact Pharma, for a comment.
Read the full interview at biostock.se:
SynAct’s CSO on resomelagon making WHO’s dengue shortlist
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/